DPP-4 inhibitors significantly increased the GLP-1 and GIP levels [13, 14, 40], reduced the glucagon levels during hyperglycemia, and sustained glucagon counterregulation during hypoglycemia in patients with T1DM [13, 14]. The gene discussed is GIP; the disease is Hyperglycemia.